Abbott Laboratories (ABT) Cash from Financing Activities (2009 - 2026)

Abbott Laboratories has disclosed Cash from Financing Activities across 18 years of filings, most recently posting $17.3 billion for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $17.3 billion, up 942.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.1 billion (up 307.85% YoY), and the FY2025 annual result was -$6.3 billion, down 16.75% from the prior year.
• Cash from Financing Activities came in at $17.3 billion for Q1 2026 at Abbott Laboratories, up from -$1.4 billion in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $17.3 billion in Q1 2026 to a low of -$3.8 billion in Q1 2022.
• The 5-year median for Cash from Financing Activities is -$1.5 billion (2022), against an average of -$536.9 million.
• Across the five-year window, Cash from Financing Activities tumbled 295.35% in 2022 and soared 942.48% in 2026, its largest moves.
• Abbott Laboratories' Cash from Financing Activities stood at -$1.5 billion in 2022, then tumbled by 40.84% to -$2.1 billion in 2023, then grew by 9.31% to -$1.9 billion in 2024, then climbed by 24.93% to -$1.4 billion in 2025, then jumped by 1339.3% to $17.3 billion in 2026.
• The last three Cash from Financing Activities figures came in at $17.3 billion (Q1 2026), -$1.4 billion (Q4 2025), and -$1.8 billion (Q3 2025), per Business Quant data.